ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 144 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $43,871,444 | -50.0% | 8,262,042 | -10.3% | 0.00% | -42.9% |
Q2 2023 | $87,797,848 | -56.4% | 9,212,786 | -49.7% | 0.01% | -22.2% |
Q1 2023 | $201,573,460 | +49.0% | 18,324,860 | +100.5% | 0.01% | -30.8% |
Q4 2022 | $135,259,760 | -20.7% | 9,139,173 | +2.4% | 0.01% | -27.8% |
Q3 2022 | $170,637,000 | +3.8% | 8,929,231 | +15.8% | 0.02% | +12.5% |
Q2 2022 | $164,357,000 | +12.9% | 7,712,680 | +2.1% | 0.02% | +33.3% |
Q1 2022 | $145,558,000 | -7.0% | 7,557,593 | +0.2% | 0.01% | 0.0% |
Q4 2021 | $156,467,000 | -13.1% | 7,544,212 | +0.1% | 0.01% | -14.3% |
Q3 2021 | $180,041,000 | -12.4% | 7,536,265 | +0.1% | 0.01% | -12.5% |
Q2 2021 | $205,514,000 | -7.0% | 7,530,740 | -1.4% | 0.02% | -15.8% |
Q1 2021 | $220,922,000 | +20.0% | 7,636,449 | +16.7% | 0.02% | +18.8% |
Q4 2020 | $184,116,000 | +9.7% | 6,545,164 | +14.3% | 0.02% | -5.9% |
Q3 2020 | $167,842,000 | -3.0% | 5,728,393 | +0.1% | 0.02% | -10.5% |
Q2 2020 | $173,069,000 | +1.7% | 5,723,182 | +0.2% | 0.02% | -20.8% |
Q1 2020 | $170,258,000 | – | 5,713,343 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |